SpringWorks Therapeutics, Inc.
SWTX
$37.06
-$0.86-2.27%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 3,058.47% | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3,417.33% | -- | -- | -- | -- |
| Cost of Revenue | 2,873.93% | -- | -- | -- | -- |
| Gross Profit | 3,462.97% | -- | -- | -- | -- |
| SG&A Expenses | 29.92% | 34.31% | 34.04% | 41.05% | 46.82% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 34.80% | 33.35% | 31.14% | 29.91% | 24.15% |
| Operating Income | 18.92% | 8.59% | -3.40% | -21.00% | -22.21% |
| Income Before Tax | 20.60% | 9.77% | -1.06% | -17.31% | -17.19% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 20.60% | 9.77% | -1.06% | -17.31% | -17.19% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 20.60% | 9.77% | -1.06% | -17.31% | -17.19% |
| EBIT | 18.92% | 8.59% | -3.40% | -21.00% | -22.21% |
| EBITDA | 19.54% | 9.13% | -2.93% | -20.65% | -21.95% |
| EPS Basic | 32.23% | 20.46% | 10.99% | -0.03% | 1.72% |
| Normalized Basic EPS | 32.23% | 20.45% | 10.98% | -0.03% | 1.72% |
| EPS Diluted | 32.23% | 20.46% | 10.99% | -0.03% | 1.72% |
| Normalized Diluted EPS | 32.23% | 20.45% | 10.98% | -0.03% | 1.72% |
| Average Basic Shares Outstanding | 17.37% | 15.19% | 14.91% | 16.56% | 18.52% |
| Average Diluted Shares Outstanding | 17.37% | 15.19% | 14.91% | 16.56% | 18.52% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |